- Home
- TRU vs UTHR Comparison
TRU vs UTHR Comparison
Compare TRU & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- UTHR
- Stock Information
- Founded
- TRU 1968
- UTHR 1996
- Country
- TRU United States
- UTHR United States
- Employees
- TRU N/A
- UTHR N/A
- Industry
- TRU Finance: Consumer Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- TRU Finance
- UTHR Health Care
- Exchange
- TRU Nasdaq
- UTHR Nasdaq
- Market Cap
- TRU 18.0B
- UTHR 16.1B
- IPO Year
- TRU 2015
- UTHR 1999
- Fundamental
- Price
- TRU $95.36
- UTHR $358.93
- Analyst Decision
- TRU Buy
- UTHR Buy
- Analyst Count
- TRU 16
- UTHR 14
- Target Price
- TRU $107.67
- UTHR $378.36
- AVG Volume (30 Days)
- TRU 1.3M
- UTHR 301.3K
- Earning Date
- TRU 02-13-2025
- UTHR 02-19-2025
- Dividend Yield
- TRU 0.44%
- UTHR N/A
- EPS Growth
- TRU N/A
- UTHR 25.10
- EPS
- TRU 1.14
- UTHR 22.72
- Revenue
- TRU $4,101,300,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- TRU $10.07
- UTHR $26.19
- Revenue Next Year
- TRU $7.92
- UTHR $10.79
- P/E Ratio
- TRU $83.41
- UTHR $15.80
- Revenue Growth
- TRU 8.53
- UTHR 25.04
- 52 Week Low
- TRU $66.07
- UTHR $208.62
- 52 Week High
- TRU $113.17
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- TRU 53.22
- UTHR 45.95
- Support Level
- TRU $86.03
- UTHR $357.55
- Resistance Level
- TRU $94.00
- UTHR $370.48
- Average True Range (ATR)
- TRU 2.34
- UTHR 8.55
- MACD
- TRU 0.66
- UTHR 0.60
- Stochastic Oscillator
- TRU 85.05
- UTHR 37.37
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries, and about a quarter of its revenue comes from international markets.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.